Citation Impact
Citing Papers
Spectrum of Phosphatidylinositol 3-Kinase Pathway Gene Alterations in Bladder Cancer
2009
rMATS: Robust and flexible detection of differential alternative splicing from replicate RNA-Seq data
2014 Standout
PIK3CA Mutations Are an Early Genetic Alteration Associated with FGFR3 Mutations in Superficial Papillary Bladder Tumors
2006
Inhibition of Activated Fibroblast Growth Factor Receptor 2 in Endometrial Cancer Cells Induces Cell Death Despite PTEN Abrogation
2008
High burden and pervasive positive selection of somatic mutations in normal human skin
2015 StandoutScience
Hyperplasia and Carcinomas in Pten-Deficient Mice and Reduced PTEN Protein in Human Bladder Cancer Patients
2006 StandoutNobel
Loss-of-Function Fibroblast Growth Factor Receptor-2 Mutations in Melanoma
2009
The 2016 revision of the World Health Organization classification of lymphoid neoplasms
2016 Standout
Molecular analysis ofPTEN andMXI1 in primary bladder carcinoma
2000
Satb1 regulates the effector program of encephalitogenic tissue Th17 cells in chronic inflammation
2019 StandoutNobel
Somatic mutation of PTEN in bladder carcinoma
1999
Genetic variation at the 8q24.21 renal cancer susceptibility locus affects HIF binding to a MYC enhancer
2016 StandoutNobel
A pupal transcriptomic screen identifies Ral as a target of store-operated calcium entry in Drosophila neurons
2017 StandoutNobel
Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
2024 Standout
Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries
2021 Standout
Somatic mutations of fibroblast growth factor receptor 3 (FGFR3) are uncommon in carcinomas of the uterine cervix
2000
Antibody-based targeting of FGFR3 in bladder carcinoma and t(4;14)-positive multiple myeloma in mice
2009
The Intronic Long Noncoding RNA ANRASSF1 Recruits PRC2 to the RASSF1A Promoter, Reducing the Expression of RASSF1A and Increasing Cell Proliferation
2013
Epithelial-mesenchymal transition and its implications for fibrosis
2003 Standout
Stromal fibroblasts in cancer initiation and progression
2004 StandoutNature
FGFR3 mutations in prostate cancer: association with low-grade tumors
2009
Brn-3b enhances the pro-apoptotic effects of p53 but not its induction of cell cycle arrest by cooperating in trans-activation of bax expression
2006
MYC on the Path to Cancer
2012 Standout
A view on drug resistance in cancer
2019 StandoutNature
The FGF family: biology, pathophysiology and therapy
2009 Standout
NFAT dysregulation by increased dosage of DSCR1 and DYRK1A on chromosome 21
2006 StandoutNature
The incidence of thanatophoric dysplasia mutations inFGFR3 gene is higher in low-grade or superficial bladder carcinomas
2001
Epithelial-Mesenchymal Transitions in Development and Disease
2009 Standout
Calcium's Role in Mechanotransduction during Muscle Development
2014 Standout
Involvement of the FGFR4 Arg388 allele in head and neck squamous cell carcinoma
2004
Cell Signaling by Receptor Tyrosine Kinases
2010 Standout
FGFR4 overexpression in pancreatic cancer is mediated by an intronic enhancer activated by HNF1α
2002
TGF-β signaling in tumor suppression and cancer progression
2001 Standout
Cancer Metastasis: Building a Framework
2006 Standout
Follicular lymphoma-like B cells of uncertain significance (in situ follicular lymphoma) may infrequently progress, but precedes follicular lymphoma, is associated with other overt lymphomas and mimics follicular lymphoma in flow cytometric studies
2013
A Molecular Brake in the Kinase Hinge Region Regulates the Activity of Receptor Tyrosine Kinases
2007
DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis
2005 StandoutNature
A Crucial Role for Fibroblast Growth Factor Signaling in Embryonic Mammary Gland Development
2004
Calcineurin Promotes Hypoxia-inducible Factor 1α Expression by Dephosphorylating RACK1 and Blocking RACK1 Dimerization
2007 StandoutNobel
Transcriptional regulation by calcium, calcineurin, and NFAT
2003 Standout
The role of fibroblast growth factor receptor 2b in skin homeostasis and cancer development
2007
Differential PTEN Protein Expression Profiles in Superficial versus Invasive Bladder Cancers
2005
Melioidosis
2012 Standout
Epithelial Cell Plasticity in Development and Tumor Progression
1999
Cellular signaling by fibroblast growth factor receptors
2005 Standout
The NOX Family of ROS-Generating NADPH Oxidases: Physiology and Pathophysiology
2007 Standout
Synthesis and biological evaluation of a triazole-based library of pyrido[2,3-d]pyrimidines as FGFR3 tyrosine kinase inhibitors
2010
NOTCHing the bone: Insights into multi-functionality
2009
Mammalian display screening of diverse cystine-dense peptides for difficult to drug targets
2017 StandoutNobel
WNT signaling in bone homeostasis and disease: from human mutations to treatments
2013 Standout
Novel fibroblast growth factor receptor 3 (FGFR3) mutations in bladder cancer previously identified in non-lethal skeletal disorders
2002
Epithelial–mesenchymal transitions in tumour progression
2002 Standout
Blinded by the Light: The Growing Complexity of p53
2009 Standout
Fibroblast growth factor signalling: from development to cancer
2010 Standout
Identification of Putative Target Genes of the Transcription Factor RUNX2
2013 StandoutNobel
MMAC1/PTEN inhibits cell growth and induces chemosensitivity to doxorubicin in human bladder cancer cells
2000
A mutation in Orai1 causes immune deficiency by abrogating CRAC channel function
2006 StandoutNature
Integration of BMP, Wnt, and notch signaling pathways in osteoblast differentiation
2011
Wnt/β-Catenin Signaling and Disease
2012 Standout
Notch signaling maintains bone marrow mesenchymal progenitors by suppressing osteoblast differentiation
2008
Bladder cancer
2016 Standout
A neonatal lethal mutation in FGFR3 uncouples proliferation and differentiation of growth plate chondrocytes in embryos
2000
Dimorphic effects of Notch signaling in bone homeostasis
2008
Targeting FGF19 inhibits tumor growth in colon cancer xenograft and FGF19 transgenic hepatocellular carcinoma models
2007
Mosaicism of activatingFGFR3 mutations in human skin causes epidermal nevi
2006
Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis
2009 Standout
Osteoclast differentiation and activation
2003 StandoutNature
The many faces of small B cell lymphomas with plasmacytic differentiation and the contribution of MYD88 testing
2015
LRP5 Mutations Linked to High Bone Mass Diseases Cause Reduced LRP5 Binding and Inhibition by SOST
2006
The roles of PTEN in development, physiology and tumorigenesis in mouse models: a tissue-by-tissue survey
2008 StandoutNobel
Frequency of fibroblast growth factor receptor 3 mutations in sporadic tumours
2001
Transformation and Stat activation by derivatives of FGFR1, FGFR3, and FGFR4
2000
MYD88 L265P mutation analysis helps define nodal lymphoplasmacytic lymphoma
2014
Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis
2005 StandoutNature
Loss of a small region around the PTEN locus is a major chromosome 10 alteration in prostate cancer xenografts and cell lines
2003
Inhibition of γ‐secretases alters both proliferation and differentiation of mesenchymal stem cells
2007
Tumor-Specific Isoform Switch of the Fibroblast Growth Factor Receptor 2 Underlies the Mesenchymal and Malignant Phenotypes of Clear Cell Renal Cell Carcinomas
2013
Basic and Therapeutic Aspects of Angiogenesis
2011 Standout
Activated Hepatic Stellate Cells Express Keratinocyte Growth Factor in Chronic Liver Disease
2004
FGFR3 and Ras gene mutations are mutually exclusive genetic events in urothelial cell carcinoma
2005
The bacterial gene lfpA influences the potent induction of calcitonin receptor and osteoclast-related genes in Burkholderia pseudomallei-induced TRAP-positive multinucleated giant cells
2006
The PI3K Pathway in Human Disease
2017 Standout
FGFR3 as a therapeutic target of the small molecule inhibitor PKC412 in hematopoietic malignancies
2005
Mutant fibroblast growth factor receptor 3 induces intracellular signaling and cellular transformation in a cell type- and mutation-specific manner
2009
Molecular mechanisms and clinical applications of angiogenesis
2011 StandoutNature
Activating mutations of the tyrosine kinase receptor FGFR3 are associated with benign skin tumors in mice and humans
2005
The role of fibroblast growth factors and their receptors in prostate cancer
2004
Hepatic Stellate Cells: Protean, Multifunctional, and Enigmatic Cells of the Liver
2008 Standout
Gene regulation by long non-coding RNAs and its biological functions
2020 Standout
The Dependence Receptor UNC5H2/B Triggers Apoptosis via PP2A-Mediated Dephosphorylation of DAP Kinase
2010
Constitutive activating mutation of theFGFR3b in oral squamous cell carcinomas
2005
Novel transcripts of fibroblast growth factor receptor 3 reveal aberrant splicing and activation of cryptic splice sequences in colorectal cancer.
2000
Click Chemistry for Drug Development and Diverse Chemical–Biology Applications
2013 Standout
Targeting the Extracellular Domain of Fibroblast Growth Factor Receptor 3 with Human Single-Chain Fv Antibodies Inhibits Bladder Carcinoma Cell Line Proliferation
2005
RBPjκ-dependent Notch signaling regulates mesenchymal progenitor cell proliferation and differentiation during skeletal development
2010 StandoutNobel
The fibroblast growth factor receptor 3 (FGFR3) mutation is a strong indicator of superficial bladder cancer with low recurrence rate.
2001
Trends in stage‐specific incidence rates for urothelial carcinoma of the bladder in the United States: 1988 to 2006
2013
Cartilage-specific RBPjκ-dependent and -independent Notch signals regulate cartilage and bone development
2012 StandoutNobel
Inducible prostate intraepithelial neoplasia with reversible hyperplasia in conditional FGFR1-expressing mice.
2003
Activated fibroblast growth factor receptor 3 is an oncogene that contributes to tumor progression in multiple myeloma
2001
Cancer progression and tumor cell motility are associated with the FGFR4 Arg(388) allele.
2002
Notch and the Skeleton
2009
PIK3CA MUTATIONS ARE AN EARLY GENETIC ALTERATION ASSOCIATED WITH FGFR3 MUTATIONS IN SUPERFICIAL PAPILLARY BLADDER TUMORS
2006
Transforming property of TEL-FGFR3 mediated through PI3-K in a T-cell lymphoma that subsequently progressed to AML
2004
Activating mutations in FGFR3 and HRAS reveal a shared genetic origin for congenital disorders and testicular tumors
2009
SATB1 Defines a Subtype of Cutaneous CD30+ Lymphoproliferative Disorders Associated with a T-Helper 17 Cytokine Profile
2018
Invasive Bladder Cancer: Genomic Insights and Therapeutic Promise
2015
Molecular correlates of gefitinib responsiveness in human bladder cancer cells
2007
FGFR4 Arg388 Allele Is Associated With Resistance to Adjuvant Therapy in Primary Breast Cancer
2006
Cancer Genome Landscapes
2013 StandoutScience
The phosphatidylinositol‐3 kinase pathway regulates bladder cancer cell invasion
2003
Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer
2015
Distinct Roles of Fibroblast Growth Factor Receptor 1 and 2 in Regulating Cell Survival and Epithelial-Mesenchymal Transition
2007
The inhibitory anti-FGFR3 antibody, PRO-001, is cytotoxic to t(4;14) multiple myeloma cells
2006
Directionally Specific Paracrine Communication Mediated by Epithelial FGF9 to Stromal FGFR3 in Two-Compartment Premalignant Prostate Tumors
2004
Fibroblast Growth Factors and Their Receptors in Transitional Cell Carcinoma
2003
Notch Inhibits Osteoblast Differentiation and Causes Osteopenia
2008
Epithelial-mesenchymal transition and its implications for fibrosis
2003 Standout
Fibroblast Growth Factor Receptor 3 Associates with and Tyrosine Phosphorylates p90 RSK2, Leading to RSK2 Activation That Mediates Hematopoietic Transformation
2009
Fibroblast Growth Factor Receptor 1 Promotes Proliferation and Survival via Activation of the Mitogen-Activated Protein Kinase Pathway in Bladder Cancer
2009
The myeloma-associated oncogene fibroblast growth factor receptor 3 is transforming in hematopoietic cells
2001
Mutations in fibroblast growth factor receptor 2 and fibroblast growth factor receptor 3 genes associated with human gastric and colorectal cancers.
2001
Works of David Cappellen being referenced
Tumour suppressive properties of fibroblast growth factor receptor 2-IIIb in human bladder cancer
1999
Oncogenic properties of the mutated forms of fibroblast growth factor receptor 3b
2005
Frequent loss of heterozygosity on chromosome 10q in muscle-invasive transitional cell carcinomas of the bladder
1997
Clinical and biological characteristics of cervical neoplasias with FGFR3 mutation.
2005
Multiple genetic alterations in primary cutaneous large B-cell lymphoma, leg type support a common lymphomagenesis with activated B-cell-like diffuse large B-cell lymphoma
2013
BCL‐2/JH translocation in peripheral blood lymphocytes of unexposed individuals: Lack of seasonal variations in frequency and molecular features
2003
Transcriptional Program of Mouse Osteoclast Differentiation Governed by the Macrophage Colony-stimulating Factor and the Ligand for the Receptor Activator of NFκB
2002
Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas
1999
Novel c‐MYC target genes mediate differential effects on cell proliferation and migration
2006
Netrin-1 acts as a survival factor for aggressive neuroblastoma
2009
Coordinated Activation of Notch, Wnt, and Transforming Growth Factor-β Signaling Pathways in Bone Morphogenic Protein 2-induced Osteogenesis
2004
High Frequency and Clinical Prognostic Value of MYD88 L265P Mutation in Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg-Type
2014
[The p53 gene].
2005
Assessment of diagnostic criteria between primary cutaneous anaplastic large-cell lymphoma and CD30-rich transformed mycosis fungoides; a study of 66 cases
2015